Clinical trial • Phase I • Immunology
JNJ-90106848 for Inflammatory conditions | Immune system disorders
Phase I trial of JNJ-90106848 for Inflammatory conditions | Immune system disorders. None/Not specified-controlled. 63 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Inflammatory conditions | Immune system disorders
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 02-06-2025
- First CTIS Authorization Date
- 11-08-2025
Trial design
None/Not specified-controlled Phase I trial across 1 site in Belgium.
- Comparator
- None/Not specified
- Target Sample Size
- 63
Recruitment
- Planned Sample Size
- 63
- Recruitment Window Months
- 11
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 63
Belgium
- Earliest CTIS Part Ii Submission Date
- 18-07-2025
- Latest Decision Or Authorization Date
- 10-10-2025
- Processing Time Days
- 84
- Number Of Sites
- 1
- Number Of Participants
- 63
Sites
- Site Name
- SGS Belgium, Drie Eikenstraat 655, Edegem
- Department Name
- SGS Clinical Pharmacology Unit
- Contact Person Name
- Katrin Van Leuven
- Contact Person Email
- Katrin.VanLeuven@sgs.com
- Number Of Participants
- 63
Sponsor
Primary sponsor
- Full Name
- Janssen Cilag International
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- JNJ-90106848
- Routes Of Administration
- Injection
- Route
- Injection
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis